by Truveta Research | Aug 22, 2025 | Research, Research Insights
Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
by Truveta Research | Aug 22, 2025 | Research, Research Insights
Authors: Amy Austin, MS ⊕Truveta, Inc, Bellevue, WA, Emily Webber, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Jared Kern ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA, Sally Omidvar, MSPH, MS ⊕Truveta, Inc,...
by Truveta staff | Aug 12, 2025 | Research
In this edition of Truveta experts, Esther Kim, PhD, MPH, Senior Director of Research Services at Truveta, shares findings from her recent exploration of the burden of sudden cardiac arrest (SCA) or sudden cardiac death (SCD), as well as cardiac arrhythmias, among...
by Truveta Research | Aug 1, 2025 | Research, Research Insights
62.7% of Lyme cases occurred between May and August, underscoring the heightened risk during late spring and summer. June consistently showed the highest activity, accounting for nearly 1 in 5 cases (19.4%) across observed years. Risk of Lyme remains elevated in...
by Truveta staff | Jul 31, 2025 | Research
Can catheter design impact patient safety? That’s the question of a new peer-reviewed study from Medical Components, Inc. (Medcomp), based on a retrospective analysis of 3,546 catheter insertions captured in Truveta Data. Used to deliver life-sustaining dialysis...
by Truveta Research | Jul 24, 2025 | Research
Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
